Tuesday, 4 December 2018

5th International Conference on Neuro-Oncology and Brain Tumor

Conference series llc LTD invites all the participants from all over the world to attend 5th International Conference on Neuro-Oncology and Brain Tumor" during February 27-28, 2019 Seoul, South Korea, which includes prompt Keynote Presentations, Oral Talks, Poster Presentations, and Exhibitions.
Conference Highlights
  •     200+ Participation (70% Industry: 30% Academia)
  •     5+ Keynote Speakers
  •     50+ Plenary Speakers
  •     5+ Exhibitors
  •     10 Innovative Educational Sessions
  •     5+ Workshops
  •     B2B Meetings
Target Audience:
We are happy to bring to your notice that Conference Series llc LTD is hosting the "5th International Conference on Neuro-Oncology and Brain Tumor" (Neuro Oncology 2019) along with external scientific association with the Academicians, Directors, Laboratory researchers, Professors, Associate Professors, Professionals, Lecturers, Scientists and students, around the globe, scheduled on February 27-28, 2019 Seoul, South Korea.
  • Neurologist
  • Neuro Oncologist
  • Psychiatrist
  • Pharmaceutical company
  • Research scholars
  • Pathologist
  • Diagnostics companies
  • Neuroscience Professors
  • Neuroradiologists
  • Researchers and others
  • Academicians
  • Neuro Pharmacologists
  • Research and Development Department.
  • Laboratory Professionals
  • Ph.D. Students
Target Audience for the conference are Physicians and Allied Health Professionals in the field of:
  •         Adult Medical Oncology and Hematology
  •         Pediatric Oncology and Hematology
  •         Neuro-Oncology
  •         Neurology
  •         Neurosurgery
  •         Radiation Oncology
  •         Neuropathology and others
Who should attend?
Scientists and Researchers, Neurologist, Neuro Oncologist, Radiologist, Biotechnologists, Medical specialists, Clinicians and Chemists from Academics, Pharmaceutical/Biotechnology/Forensic/Environmental Industries, Laboratories working in the accompanying regions/field:
  • Directors
  • Head of Department
  • Professors
  • Industrial Researchers
  • Neuro-oncologist
  • Radiation Oncologists
  • Oncologists
  • Neuropediatricians
  • Neurophysiologists
  • Neurosurgeons
  • Neurologist
  • Neuroradiologist
  • Neuro-Pathologists
  • Rehabilitation Specialists
  • Nurses
  • Neuroscience Researchers and Students from academia in the research of Neuro-oncology, Neurooncology Associations, Brain tumour societies
Benefits of Attending the Conference:
  • Networking Opportunities, Grow Your Professional Network
  • Build Your Knowledge Base
  • Expand Your Resources
  • Meet Experts & Influencers Face to Face
  • Learning in a New Space
  • Break Out of Your Comfort Zone
  • New Tips & Tactics
  • Greater Focus
  • Top Industries Representation
  • Abstracts will be published in the conference souvenir and respective International journals
  • Each Abstract will receive unique (DOI) Number provided by Cross Ref
  • Website visibility to more than 35K visitors in less than 6 months
  •  Laudable talks by the top-notch of the Global Scientific Community
  • The Serendipity of the Random Workshop
  • Will be felicitated with International Organizing Committee Member (IOCM)
  • Remarkable Awards and Global Recognition to meritorious Researchers

Kindly contact the below e-mail id : neurooncology@conferenceint.com

Thursday, 29 November 2018

Predicting cancer outcomes from histology and genomics using convolutional networks

Predicting the expected outcome of patients diagnosed with cancer is a critical step in treatment. Advances in genomic and imaging technologies provide physicians with vast amounts of data, yet prognostication remains largely subjective, leading to suboptimal clinical management. We developed a computational approach based on deep learning to predict the overall survival of patients diagnosed with brain tumors from microscopic images of tissue biopsies and genomic biomarkers. This method uses adaptive feedback to simultaneously learn the visual patterns and molecular biomarkers associated with patient outcomes. Our approach surpasses the prognostic accuracy of human experts using the current clinical standard for classifying brain tumors and presents an innovative approach for objective, accurate, and integrated prediction of patient outcomes.

#Register now to #avail #early #bird #offers, and be a #part of this #great #event #Neurooncology2019, which is going to happen in #Seoul,South kOrea #February.Only #few more #speaker #slots are #available.#Grab the #opportunity and #seize your #slot.
For more details regarding conference registration:https://neurooncology.conferenceseries.com/registration.php

Kindly contact the below e-mail id :mili052biswal@gmail.com, neurooncology@conferenceint.com


Monday, 26 November 2018

Researchers find leukemia and lymphoma drug may benefit glioblastoma patients



slowed brain tumor growth in a preclinical model and extended survival more than 10-times the rate of the current standard-of-care chemotherapy drug.
in human glioblastoma cells that ibrutinib works by inhibiting glioma stem cells—an aggressive type of brain cancer cell that tends to resist treatment and spread. Furthermore, dr showed  that combining ibrutinib with radiation therapy prevents glioblastoma cells from developing this resistance. Combination therapy overcame resistance and extended lifespan more effectively than either radiation or ibrutinib treatment alone.
According to the Dr's  are said glioblastoma survival is very poor—median survival in patients undergoing standard treatment is less than 15 months. Glioblastoma is the most lethal primary brain tumor and is highly resistant to current therapies," There is an urgent need to get new treatments to these patients as quickly as possible."
In earlier studies, Dr's are found that glioma stem cells have high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transducer and activator of transcription 3), which is responsible for the aggressive, pro-cancer qualities of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting both proteins.
"Additional research is important to understand the effects of ibrutinib in patients, but these early findings are promising," "Using an FDA-approved drug would allow us to surpass many of the lengthy regulatory studies needed when developing a new treatment, and we could potentially begin clinical trials very soon."
Ibrutinib (Imbruvica) has been approved by the U.S. Food & Drug Administration to treat certain types of leukemia and lymphoma, as well as chronic graft versus host disease.

Kindly contact the below e-mail id : neurooncology@conferenceint.com



Tuesday, 20 November 2018

Modified polio vaccine helps fight deadly brain tumors .

Modified polio vaccine helps fight deadly brain tumor

Modified polio vaccine helps fight deadly brain tumors
Some patients with 'dismal' prognosis were alive as long as six years later
A modified version of the polio vaccine, infused straight into aggressive brain tumors, helped some patients live for years longer than they normally
It’s no miracle cure — only about 20 percent of patients with gliomas were helped — but some are alive six years later
It’s a hopeful enough finding to move forward and test the vaccine in more people.
Standard treatment of brain tumors includes surgery if the tumor is somewhere reachable; chemotherapy; and radiation. But if the tumor is aggressive, it’s usually fatal.
These are people who failed everything,” Bigner said. “Virtually all patients, no matter what you treat them with, are dead within in two years.”

About a third of all brain tumors are gliomas, according to the Brain Tumor Society. About 80,000 people a year are diagnosed with a brain tumor, and about 24,000 of those are malignant. “The average survival rate for all malignant brain tumor patients is only 34.7 percent,”
But there’s evidence that some viruses can home in on tumors and kill them. It’s not clear why, but viruses can also make tumors more visible to the immune system.
They infused various doses into the tumors of the 61 glioma patients.

“We inject the virus directly into brain tumors and it kills all the tumor cells it comes in contact with,” Bigner said. “The most important thing is, it sets up a secondary immune response and really destroys the distant tumor cells.”


Kindly contact the below e-mail id : neurooncology@conferenceint.com


Friday, 16 November 2018

Conference series llc LTD invites all the participants from all over the world to attend 5th International Conference on Neuro-Oncology and Brain Tumor" during February 27-28, 2019 Seoul, South Korea, which includes prompt Keynote Presentations, Oral Talks, Poster Presentations, and Exhibitions.
Conference Highlights
  •     200+ Participation (70% Industry: 30% Academia)
  •     5+ Keynote Speakers
  •     50+ Plenary Speakers
  •     5+ Exhibitors
  •     10 Innovative Educational Sessions
  •     5+ Workshops
  •     B2B Meetings
Target Audience:
We are happy to bring to your notice that Conference Series llc LTD is hosting the "5th International Conference on Neuro-Oncology and Brain Tumor" (Neuro Oncology 2019) along with external scientific association with the Academicians, Directors, Laboratory researchers, Professors, Associate Professors, Professionals, Lecturers, Scientists and students, around the globe, scheduled on February 27-28, 2019 Seoul, South Korea.
  • Neurologist
  • Neuro Oncologist
  • Psychiatrist
  • Pharmaceutical company
  • Research scholars
  • Pathologist
  • Diagnostics companies
  • Neuroscience Professors
  • Neuroradiologists
  • Researchers and others
  • Academicians
  • Neuro Pharmacologists
  • Research and Development Department.
  • Laboratory Professionals
  • Ph.D. Students
Target Audience for the conference are Physicians and Allied Health Professionals in the field of:
  •         Adult Medical Oncology and Hematology
  •         Pediatric Oncology and Hematology
  •         Neuro-Oncology
  •         Neurology
  •         Neurosurgery
  •         Radiation Oncology
  •         Neuropathology and others
Who should attend?
Scientists and Researchers, Neurologist, Neuro Oncologist, Radiologist, Biotechnologists, Medical specialists, Clinicians and Chemists from Academics, Pharmaceutical/Biotechnology/Forensic/Environmental Industries, Laboratories working in the accompanying regions/field:
  • Directors
  • Head of Department
  • Professors
  • Industrial Researchers
  • Neuro-oncologist
  • Radiation Oncologists
  • Oncologists
  • Neuropediatricians
  • Neurophysiologists
  • Neurosurgeons
  • Neurologist
  • Neuroradiologist
  • Neuro-Pathologists
  • Rehabilitation Specialists
  • Nurses
  • Neuroscience Researchers and Students from academia in the research of Neuro-oncology, Neurooncology Associations, Brain tumour societies
Benefits of Attending the Conference:
  • Networking Opportunities, Grow Your Professional Network
  • Build Your Knowledge Base
  • Expand Your Resources
  • Meet Experts & Influencers Face to Face
  • Learning in a New Space
  • Break Out of Your Comfort Zone
  • New Tips & Tactics
  • Greater Focus
  • Top Industries Representation
  • Abstracts will be published in the conference souvenir and respective International journals
  • Each Abstract will receive unique (DOI) Number provided by Cross Ref
  • Website visibility to more than 35K visitors in less than 6 months
  •  Laudable talks by the top-notch of the Global Scientific Community
  • The Serendipity of the Random Workshop
  • Will be felicitated with International Organizing Committee Member (IOCM)
  • Remarkable Awards and Global Recognition to meritorious Researchers

Tuesday, 13 November 2018

#Neurooncology2019 provides you with a #unique #opportunity to meet up with #peers from both #industry and #academia . We cordially #invite all concerned people to #join us at our #event and make it #successful by your #participation at #SouthKorea #February 27-28,2019
https://neurooncology.conferenceseries.com/abstract-submission.php
more details regarding conference: https://neurooncologyconference.blogspot.com/
Kindly contact the below e-mail id :mili052biswal@gmail.com, neurooncology@conferenceint.com

Tuesday, 6 November 2018


After successfully completion of #Neurooncology2018 we are happy to invite you at our upcoming conference “5th International Conference Neuro-Oncology and Brain Tumor #Neurooncology2019” scheduled during February 27-28, 2019 at Seoul, South Korea along with external scientific association with the #researchers#industry #professionals, decision makers, and #academicians to gather and exchange ideas.
#NeuroOncology 2019 would lay a platform for the interaction with experts around the world and aims in accelerating scientific with a theme: “Future challenges and the latest Impact Factor for Neuro-Oncology and Brain Tumor”
For more details regarding conference: https://neurooncologyconference.blogspot.com/

Kindly contact the below e-mail id :mili052biswal@gmail.com, neurooncology@conferenceint.com